Tags : Boehringer Ingelheim (BI)


Boehringer Ingelheim (BI) & Eli Lilly Reports RWE Results of

Shots:   The EMPRISE study involves assessing of Jardiance vs DPP-4 inhibitors in ~35,000 people with T2D initiated from 2014 to 2019, demonstrated 44% reduction in relative risk of hospitalization for HHF and was consistent in patients with or without CV diseases The above results support finding from EMPA-REG OUTCOME trial assessing jardiance (10/25 mg […]Read More